KODIAK SCIENCES INC. Increase Decrease In Operating Lease Liability
KODIAK SCIENCES INC. (KOD) reported Increase Decrease In Operating Lease Liability of -$6.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- KODIAK SCIENCES INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$3.24M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$3.19M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$3.02M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$3.01M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for fiscal 2025 was -$11.16M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for fiscal 2024 was -$11.25M.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for fiscal 2023 was -$8.92M, a 212.84% decline from fiscal 2022.
- KODIAK SCIENCES INC. increase decrease in operating lease liability for fiscal 2022 was $7.91M, a 335.89% increase from fiscal 2021.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$6.42M 10-Q · filed 2026-08-13 | -$9.45M derived: sum of 3 quarters · filed 2026-08-13 | -$12.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$3.19M 10-Q · filed 2026-05-07 | -$6.21M derived: sum of 2 quarters · filed 2026-05-07 | -$9.22M derived: sum of 3 quarters · filed 2026-05-07 | -$11.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$6.03M derived: sum of 2 quarters · filed 2026-03-31 | -$8.46M derived: sum of 3 quarters · filed 2026-08-13 | -$11.16M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.44M derived: sum of 2 quarters · filed 2026-08-13 | -$8.14M 10-Q · filed 2025-11-13 | -$11.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$5.13M 10-Q · filed 2026-08-13 | -$8.22M derived: sum of 3 quarters · filed 2026-08-13 | -$10.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.71M 10-Q · filed 2026-05-07 | -$5.80M derived: sum of 2 quarters · filed 2026-05-07 | -$8.12M derived: sum of 3 quarters · filed 2026-05-07 | -$10.68M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.41M derived: sum of 2 quarters · filed 2026-03-31 | -$7.97M derived: sum of 3 quarters · filed 2026-03-31 | -$11.25M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.88M derived: sum of 2 quarters · filed 2025-11-13 | -$8.16M 10-Q · filed 2025-11-13 | -$10.00M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$5.84M 10-Q · filed 2025-08-13 | -$7.68M derived: sum of 3 quarters · filed 2026-03-31 | -$10.19M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | -$3.27M 10-Q · filed 2025-05-14 | -$5.12M derived: sum of 2 quarters · filed 2026-03-31 | -$7.63M derived: sum of 3 quarters · filed 2026-03-31 | -$9.59M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.35M derived: sum of 2 quarters · filed 2026-03-31 | -$6.32M derived: sum of 3 quarters · filed 2026-03-31 | -$8.92M 10-K · filed 2026-03-31 |
| 2023-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.47M derived: sum of 2 quarters · filed 2024-11-14 | -$7.08M 10-Q · filed 2024-11-14 | -$7.17M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | -$1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.57M 10-Q · filed 2024-08-14 | -$4.67M derived: sum of 3 quarters · filed 2025-03-27 | -$3.62M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | -$2.61M 10-Q · filed 2024-05-15 | -$2.70M derived: sum of 2 quarters · filed 2025-03-27 | -$1.66M derived: sum of 3 quarters · filed 2025-03-27 | $3.97M derived: sum of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | -$97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $948.00K derived: sum of 2 quarters · filed 2025-03-27 | $6.58M derived: sum of 3 quarters · filed 2025-03-27 | $7.91M 10-K · filed 2025-03-27 |
| 2022-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $6.68M derived: sum of 2 quarters · filed 2023-11-14 | $8.00M 10-Q · filed 2023-11-14 | $8.85M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $6.96M 10-Q · filed 2023-08-14 | $7.81M derived: sum of 3 quarters · filed 2024-03-28 | $8.43M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-15 | $2.18M derived: sum of 2 quarters · filed 2024-03-28 | $2.79M derived: sum of 3 quarters · filed 2024-03-28 | $3.23M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.47M derived: sum of 2 quarters · filed 2024-03-28 | $1.90M derived: sum of 3 quarters · filed 2024-03-28 | $1.81M 10-K · filed 2024-03-28 |
| 2021-09-30 | $619.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.05M derived: sum of 2 quarters · filed 2022-11-09 | $966.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $347.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$84.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$146.00K 10-K · filed 2023-03-28 | |||
| 2019-12-31 | -$383.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |